Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 12, Issue 16, 2006, Pages 2563-2568

  Maurizio, Soresi ^a   Lydia, Giannitrapani ^a   Fabio, D'Antona ^a   Maria, Florena Ada ^a   Emanuele, La Spada ^a   Angela, Terranova ^a   Melchiorre, Cervello ^b   Natale, D'Alessandro ^a   Giuseppe, Montalto ^a,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR   (Italy)

^c Divisione di Medicina Interna   (Italy)

Author keywords

Chronic liver disease; Cytokine; Immunohistochemistry; Interleukin 6

Indexed keywords

BIOTIN; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; POLYCLONAL ANTIBODY; STREPTAVIDIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; CELL MEMBRANE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; CYTOPLASM; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; RABBIT; STATISTICAL SIGNIFICANCE; TISSUE SECTION; TUMOR VOLUME;

EID: 33646458250     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i16.2563     Document Type: Article

References (36)

1. Oka M, Iizuka N, Yamamoto K, Gondo T, Abe T, Hazama S, Akitomi Y, Koishihara Y, Ohsugi Y, Ooba Y, Ishihara T, Suzuki T. The influence of interleukin -6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 1996; 16: 1001-1006
2. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989; 250: 607-610
3. Lee JD, Sievers TM, Skotzko M, Chandler CF, Morton DL, McBride WH, Economou JS. Interleukin-6 production by human melanoma cell lines. Lymphokine Cytokine Res 1992; 11: 161-166
4. Siegall CB, Schwab G, Nordan RP, FitzGerald DJ, Pastan I. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res 1990; 50: 7786-7788
5. Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 1990; 50: 6959-6965
6. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84: 2008-2011
7. Tsukamoto T, Kumamoto Y, Miyao N, Masumori N, Takahashi A, Yanase M. Interleukin-6 in renal cell carcinoma. J Urol 1992; 148: 1778-1781; discussion 1781-1782
8. Seguchi T, Yokokawa K, Sugao H, Nakano E, Sonoda T, Okuyama A. Interleukin-6 activity in urine and serum in patients with bladder carcinoma. J Urol 1992; 148: 791-794
9. Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T, Ogura T. Serum levels of interleukin-6 in patients with lung cancer. Br J Cancer 1995; 71: 1095-1098
10. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1991; 164: 1038-1042; discussion 1042-1043
11. Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Iizuka N, Hazama S, Hirazawa K, Hayashi H, Tangoku A, Hirose K, Ishihara T, Suzuki T. Relationship between serum levels of interleukin 6, various disease parameters, and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 1996; 56: 2776-2780
12. Wu CW, Wang SR, Chao MF, Wu TC, Lui WY, Peng FK, Chi CW. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 1996; 91: 1417-1422
13. Kishimoto T, Hirano T. Molecular regulation of B lymphocyte response. Annu Rev Immunol 1988; 6:485-512
14. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86: 1243-1254
15. Honda M, Yamamoto S, Cheng M, Yasukawa K, Suzuki H, Saito T, Osugi Y, Tokunaga T, Kishimoto T. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol 1992; 148: 2175-2180
16. Sun Y, Tokushige K, Isono E, Yamauchi K, Obata H. Elevated serum interleukin-6 levels in patients with acute hepatitis. J Clin Immunol 1992; 12:192-200
17. Deviere J, Content J, Denys C, Vandenbussche P, Schandene L, Wybran J, Dupont E. High interleukin-6 serum levels and increased production by leucocytes in alcoholic liver cirrhosis. Correlation with IgA serum levels and lymphokines production. Clin Exp Immunol 1989; 77:221-225
18. Kakumu S, Shinagawa. T, Ishikawa. T, Yoshioka K, Wakita T, Ida N. Interleukin 6 production by peripheral blood mononuclear cells in patients with chronic hepatitis B virus infection and primary biliary cirrhosis. Gastroenterol Jpn 1993; 28: 18-24
19. Huang YS, Hwang SJ, Chan CY, Wu JC, Chao Y, Chang FY, Lee SD. Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study. Zhonghua Yi Xue Za Zhi 1999; 62: 327-333
20. Malaguarnera M, Di Fazio I, Romeo MA, Restuccia S, Laurino A, Trovato BA. Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus. J Gastroenterol 1997; 32: 211-215
21. Chau GY, Wu CW, Lui WY, Chang TJ, Kao HL, Wu LH, King KL, Loong CC, Hsia CY, Chi CW. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 2000; 231: 552-558
22. Malaguarnera M, Di Fazio I, Laurino A, Romeo MA, Giugno I, Trovato BA. Role of interleukin-6 in hepatocellular carcinoma. Bull Cancer 1996; 83: 379-384
23. Goydos JS, Brumfield AM, Frezza E, Booth A, Lotze MT, Carty SE. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 1998; 227:398-404
24. Giannitrapani L, Cervello M, Soresi M, Notarbartolo M, La Rosa M, Virruso L, D'Alessandro N, Montalto G. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. Ann N Y Acad Sci 2002; 963: 46-52
25. Maione D, Di Carlo E, Li W, Musiani P, Modesti A, Peters M, Rose-John S, Della Rocca C, Tripodi M, Lazzaro D, Taub R, Savino R, Ciliberto G. Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J 1998; 17:5588-5597
26. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima. Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-928
27. Genesca J, Gonzalez A, Segura R, Catalan R, Marti R, Varela E, Cadelina G, Martinez M, Lopez-Talavera JC, Esteban R, Groszmann RJ, Guardia J. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol 1999; 94: 169-177
28. Wierzbowska A, Urbanska-Rys H, Robak T. Circulating IL-6 type cytokines and sIL-6R in patients with multiple myeloma. Br J Haematol 1999; 105: 412-419
29. Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 1999; 85: 2526-2531
30. Matsuguchi T, Okamura S, Kawasaki C, Niho Y. Production of interleukin-6 from human liver cell lines: production of interleukin-6 is not concurrent with the production of alpha-fetoprotein. Cancer Res 1990; 50: 7457-7459
31. Kumagai N, Tsuchimoto K, Tsunematsu S, Toda K, Takeuchi O, Saito H, Morizane T, Tsuchiya M, Ishii H. Inhibition of growth of human hepatoma cells by dual-function antisense IL-6 oligonucleotides. Hepatol Res 2002; 22:119-126
32. Cervello M, Notarbartolo M, Landino M, Cusimano A, Virruso L, Montalto G, D'Alessandro N. Downregulation of wild-type beta-catenin expression by interleukin 6 in human hepatocarcinoma HepG2 cells: a possible role in the growth-regulatory effects of the cytokine? Eur J Cancer 2001; 37: 512-519
33. Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travali S, D'Alessandro N. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 1999; 85: 134-144
34. Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 1993; 120:1281-1288
35. Tanner J, Tosato G. Impairment of natural killer functions by interleukin-6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest 1991; 88: 239-247
36. Demartis A, Bernassola F, Savino R, Melino G, Ciliberto G. Interleukin-6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Res 1996; 56: 4213-4218